WebMar 25, 2024 · Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology, reported full year 2024 annual results. ... HBM's cutting-edge fully human antibody platforms enable unique innovation and differentiation. WebApr 7, 2024 · Harbour BioMed ("HBM", "the Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today ...
Harbour BioMed Announces Dosing of First Patients in …
WebAug 27, 2024 · CAMBRIDGE, Mass. & WILMINGTON, N.C.--(BUSINESS WIRE)--Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company, and Pharmaceutical Product Development, LLC (PPD), a leading global ... WebApr 3, 2024 · Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on ... psychiatry group kirby whitten
Harbour BioMed Reports Full Year 2024 Financial Results
WebApr 3, 2024 · Harbour BioMed (“HBM” or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual results of full year 2024. “2024 has been our second … WebCAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2024 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and … WebFeb 21, 2024 · Harbour BioMed. Feb 21, 2024, 07:29 ET. CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 21, 2024 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that China ... psychiatry greenwood village